In Europe, Palbociclib is recommended for patients with advanced or metastatic HR+ and HER2− BC, either in association with anti-aromatase or with letrozole or fulvestrant for patients having already received endocrine therapy. This evidence concerns the gene ERBB2 and breast cancer.